Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Inclusion Criteria: * Pathologically confirmed adenocarcinoma of the esophagus, GEJ or stomach. * Stage IV disease or locally advanced/unresectable tumors * Prior progression on only 1 line of chemotherapy in the advanced/metastatic setting containing a fluoropyrimidine and/or platinum compound * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Exclusion Criteria: * Prior treatment with a taxane is not permitted in the dose-expansion phase. Patients in the dose escalation component may have received a taxane in the peri-operative setting, provided they developed disease recurrence \>6 months after the completion of this therapy * Known pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis) * Patients with any clinically apparent ascites or who have undergone a paracentesis within 7 days of enrollment * Uncontrolled hypertension (systolic pressure \>140 mm Hg or diastolic pressure \> 90 mm Hg on repeated measurement) despite optimal medical management * Active or clinically significant cardiac disease * Patients with arterial thrombotic events, such as cerebrovascular accident or myocardial infarction, within 6 months of enrollment